MX9709914A - Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. - Google Patents

Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.

Info

Publication number
MX9709914A
MX9709914A MX9709914A MX9709914A MX9709914A MX 9709914 A MX9709914 A MX 9709914A MX 9709914 A MX9709914 A MX 9709914A MX 9709914 A MX9709914 A MX 9709914A MX 9709914 A MX9709914 A MX 9709914A
Authority
MX
Mexico
Prior art keywords
alkylamino
alkoxy
aryl
radicals
compounds
Prior art date
Application number
MX9709914A
Other languages
English (en)
Inventor
George Chang
Peter H Dorff
George J Quallich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB1995/000448 external-priority patent/WO1996040640A1/en
Publication of MX9709914A publication Critical patent/MX9709914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos de formula I (Ver Formula) en la que X, Y, y Z son como se ha definido en la memoria descriptiva. Los compuestos son utiles para disminuir la secrecion de apoB y son utiles en el tratamiento de estadso tales como la aterosclerosis.
MX9709914A 1995-06-07 1995-06-07 Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. MX9709914A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000448 WO1996040640A1 (en) 1995-06-07 1995-06-07 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Publications (1)

Publication Number Publication Date
MX9709914A true MX9709914A (es) 1998-03-31

Family

ID=11004342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9709914A MX9709914A (es) 1995-06-07 1995-06-07 Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.

Country Status (20)

Country Link
US (1) US5919795A (es)
KR (1) KR100225713B1 (es)
AR (1) AR003424A1 (es)
AT (1) ATE233734T1 (es)
AU (1) AU703493B2 (es)
BG (1) BG62442B1 (es)
CO (1) CO4440626A1 (es)
DE (1) DE69529849T2 (es)
DK (1) DK0832069T3 (es)
DZ (1) DZ2045A1 (es)
IL (3) IL135376A (es)
MA (1) MA23895A1 (es)
MX (1) MX9709914A (es)
OA (1) OA10363A (es)
RO (1) RO116897B1 (es)
RU (1) RU2141478C1 (es)
TN (1) TNSN96085A1 (es)
TR (1) TR199600481A2 (es)
TW (1) TW476756B (es)
YU (1) YU35296A (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0902785T3 (da) * 1996-04-30 2002-10-07 Pfizer Fremgangsmåder og mellemprodukter til fremstilling af 4'-trifluormethylbiphenyl-2-carboxylsyre-[2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]amid
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
EP1259484B1 (en) * 2000-01-18 2005-05-18 Novartis AG Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US6953671B2 (en) * 2001-02-23 2005-10-11 The Trustees Of Columbia University In The City Of New York Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action
PL367680A1 (en) 2001-06-28 2005-03-07 Pfizer Products Inc. Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003077874A2 (en) * 2002-03-13 2003-09-25 The University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
EP1687299A1 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar
CA2555133A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
NZ563009A (en) * 2005-04-19 2011-05-27 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
PL2666859T3 (pl) * 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
CA2666191C (en) * 2006-10-09 2017-07-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
EP2126079A1 (en) * 2007-03-22 2009-12-02 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
MX2011003951A (es) * 2008-10-29 2011-05-03 Hoffmann La Roche Nuevos derivados de fenilamida o de piridilamida y su uso como agonistas de receptor acoplado a proteina g (gpbar1).
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
CA2817093A1 (en) * 2010-11-15 2012-05-24 Abbvie Inc. Nampt inhibitors
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US3905982A (en) * 1973-07-23 1975-09-16 Searle & Co 1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds
JPS5237048B2 (es) * 1973-08-18 1977-09-20
HU174697B (hu) * 1976-12-30 1980-03-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 6,7-dimetoksi-1,2,3,4-tetragidro-1-izokinolin-acetamida
JPS5967246A (ja) * 1982-09-10 1984-04-16 ザ・ウエルカム・フアウンデ−シヨン・リミテツド 置換ビフエニル化合物
DK8386A (da) * 1986-01-15 1987-07-09 Tpo Pharmachim Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme
DE3734385A1 (de) * 1987-10-10 1989-04-20 Hoechst Ag Verwendung der (alpha)-modifikation von cis-naphthoylen-bis-benzimidazol zum pigmentieren von polyolefinen
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
YU23499A (sh) * 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a

Also Published As

Publication number Publication date
BG100637A (bg) 1997-03-31
BG62442B1 (bg) 1999-11-30
RO116897B1 (ro) 2001-07-30
AU703493B2 (en) 1999-03-25
OA10363A (en) 2001-11-15
DE69529849T2 (de) 2003-09-04
KR970003589A (ko) 1997-01-28
IL135376A0 (en) 2001-05-20
RU2141478C1 (ru) 1999-11-20
DZ2045A1 (fr) 2002-07-21
YU35296A (sh) 1999-06-15
IL135377A (en) 2001-05-20
TNSN96085A1 (fr) 2005-03-15
DK0832069T3 (da) 2003-04-22
IL135375A0 (en) 2001-05-20
MA23895A1 (fr) 1996-12-31
CO4440626A1 (es) 1997-05-07
IL135375A (en) 2001-07-24
ATE233734T1 (de) 2003-03-15
AR003424A1 (es) 1998-08-05
IL135377A0 (en) 2001-05-20
TR199600481A2 (tr) 1996-12-21
US5919795A (en) 1999-07-06
DE69529849D1 (de) 2003-04-10
AU5478496A (en) 1996-12-19
KR100225713B1 (ko) 1999-10-15
IL135376A (en) 2001-05-20
TW476756B (en) 2002-02-21

Similar Documents

Publication Publication Date Title
MX9709914A (es) Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
ATE13422T1 (de) Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.
HUT65618A (en) Process for producing benzylidene-carbamoyl-2-pyrrolidone, -4-oxazolidinone, -4-thiazolidinone and -3-isothiazolidinone analogues
EP1052254A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVES AND DRUGS PRODUCED FROM SUCH DERIVATIVES
KR940005633A (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
NZ334186A (en) Neurotrophic heterocyclic esters and amides with an affinity to FKBP-type immunophilins
HRP940373A2 (en) Phenyl heterocycles as cyclooxigenase-2 inhibitors
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
DE69432973D1 (de) Verwendung von thiazolidindionen zur behandlung von atherosklerose und essstörungen
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
PL299513A1 (en) Fluorotaxoles
FR2718137B1 (fr) Procédé de préparation de trialcoylsilyl-7 baccatine III.
ES2090238T3 (es) Derivados benzhidriloxietilpiperidilos de acidos alifaticos y su aplicacion en el tratamiento del asma y de sus alergias.
CA2223574A1 (en) Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein b (apo b) secretion
ATE421878T1 (de) Verfahren zur unterdrückung oder umkehrung der tau-filament-bildungspolymerisation
ES8405619A1 (es) Procedimiento de preparacion de nuevas n-(5-aminometil 2-oxazolin 2-il)-n'-fenilureas
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
DE59304710D1 (de) Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
HU9200425D0 (en) Process for the production of disubstituted carbamide- and tiocarbamide derivatives
BR8401710A (pt) Processo para a preparacao de fenetilsulfonamidas n-sulfeniladas,composicoes praguicidas e processos para o combate as pragas e para a preparacao de composicoes
KR940005541A (ko) 치환된 벤조에이트 유도체
ATE314059T1 (de) VERWENDUNG VON ßXYLYLOXY ALKYL AMINESß FÜR DIE BEHANDLUNG VON TINNITUS
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche
DK0835265T3 (da) Blodpladeaggregeringsinhibitorer indeholdende C-terminale aminosyrerester med aminerge sidekæder

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees